TRDA Entrada Therapeutics, Inc.
Nasdaq · SEC CIK 1689375 · EDGAR
- Bought, last 12 months
- $1.64M 3 purchases by 3 insiders
- Sold, last 12 months
- $15.10M 21 sales by 7 insiders
- Filings on record
- 221 since 2021-11-01, latest 2026-09-09 19:24
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| PARMAR KUSH | Dir, 10% | — | $3.65M |
| MPM BIOVENTURES 2018, L.P. | 10% | — | $3.60M |
| MPM BioVentures 2014, L.P. | 10% | — | $3.60M |
| 5AM Ventures V, L.P. | 10% | — | $3.00M |
| Baker Bros. Advisors (GP) LLC | 10% | $1.35M | — |
| WENTWORTH KORY JAMES | CFO | — | $433.6K |
| Dowden Nathan J | Pres, COO | — | $425.7K |
| Sethuraman Natarajan | Pres, Research, Develop | — | $398.8K |
| BAKER FELIX | 10% | $261.8K | — |
| Zeiher Bernhardt G | Dir | $29.3K | — |
Transactions 229
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-05 | 2024-03-04+ | TRDA | WENTWORTH KORY JAMES | CFO | F - Tax | $12.50 | -2,215 | 80.1K | -3% | -$27.7K |
| D | 2024-03-05 | 2024-03-01 | TRDA | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +30.9K | 80.5K | +62% | $0 |
| 2024-02-20 | 2024-02-15 | TRDA | Doshi Dipal | CEO, Dir | S - Sale | $15.00 | -1,000 | 243.3K | -0.4% | -$15.0K | |
| 2024-01-18 | 2024-01-16 | TRDA | Doshi Dipal | CEO, Dir | S - Sale | $15.99 | -1,000 | 244.3K | -0.4% | -$16.0K | |
| DM | 2023-12-26 | 2023-12-21+ | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +12.5K | 59.8K | +26% | +$26.2K |
| DM | 2023-12-26 | 2023-12-21+ | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $15.59 | -12.5K | 49.6K | -20% | -$194.8K |
| 2023-12-22 | 2023-12-20 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $15.00 | -1,000 | 245.3K | -0.4% | -$15.0K | |
| 2023-11-13 | 2023-11-13 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $16.23 | -1,000 | 246.3K | -0.4% | -$16.2K | |
| 2023-10-19 | 2023-10-17 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $15.00 | -1,000 | 247.3K | -0.4% | -$15.0K | |
| 2023-09-15 | 2023-09-13 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $15.00 | -1,000 | 248.3K | -0.4% | -$15.0K | |
| D | 2023-09-06 | 2023-09-05 | TRDA | Dowden Nathan J | COO | F - Tax | $14.46 | -436 | 49.1K | -0.9% | -$6,305 |
| DM | 2023-09-06 | 2023-09-06 | TRDA | Dowden Nathan J | COO | S - Sale | $13.47 | -972 | 48.2K | -2% | -$13.1K |
| D | 2023-09-06 | 2023-09-01 | TRDA | Dowden Nathan J | COO | A - Grant | $0.00 | +14.2K | 49.6K | +40% | $0 |
| D | 2023-09-06 | 2023-09-05 | TRDA | WENTWORTH KORY JAMES | CFO | F - Tax | $14.46 | -426 | 50.5K | -0.8% | -$6,160 |
| D | 2023-09-06 | 2023-09-01 | TRDA | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +14.2K | 50.9K | +39% | $0 |
| DM | 2023-09-06 | 2023-09-06 | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale | $13.48 | -950 | 49.6K | -2% | -$12.8K |
| D | 2023-09-06 | 2023-09-05 | TRDA | Doshi Dipal | Pres, CEO, Dir | F - Tax | $14.46 | -1,440 | 249.3K | -0.6% | -$20.8K |
| D | 2023-09-06 | 2023-09-01 | TRDA | Doshi Dipal | Pres, CEO, Dir | A - Grant | $0.00 | +49.6K | 250.7K | +25% | $0 |
| D | 2023-09-06 | 2023-09-05 | TRDA | Sethuraman Natarajan | CSO | F - Tax | $14.46 | -449 | 167.2K | -0.3% | -$6,493 |
| D | 2023-09-06 | 2023-09-01 | TRDA | Sethuraman Natarajan | CSO | A - Grant | $0.00 | +14.2K | 167.6K | +9% | $0 |
| D | 2023-09-06 | 2023-09-01 | TRDA | KREHER NERISSA | Chief Medical Off | A - Grant | $0.00 | +14.2K | 41.3K | +52% | $0 |
| DM | 2023-09-06 | 2023-09-06 | TRDA | KREHER NERISSA | Chief Medical Off | S - Sale | $13.47 | -892 | 40.1K | -2% | -$12.0K |
| D | 2023-09-06 | 2023-09-05 | TRDA | KREHER NERISSA | Chief Medical Off | F - Tax | $14.46 | -401 | 40.9K | -1.0% | -$5,798 |
| 2023-08-16 | 2023-08-14 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $15.67 | -1,000 | 201.1K | -0.5% | -$15.7K | |
| DM | 2023-08-04 | 2023-08-02+ | TRDA | KREHER NERISSA | Chief Medical Off | M - OptEx | $2.10 | +26.7K | 37.5K | +248% | +$56.1K |
| DM | 2023-08-04 | 2023-08-02+ | TRDA | KREHER NERISSA | Chief Medical Off | S - Sale+OE | $14.76 | -26.7K | 27.1K | -50% | -$394.2K |
| DM | 2023-07-12 | 2023-07-10+ | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +10.0K | 42.9K | +30% | +$21.0K |
| DM | 2023-07-12 | 2023-07-10+ | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $17.99 | -10.0K | 36.7K | -21% | -$179.9K |
| M | 2023-07-12 | 2023-07-10+ | TRDA | Dowden Nathan J | COO | S - Sale | $18.03 | -7,097 | 39.3K | -15% | -$127.9K |
| M | 2023-07-12 | 2023-07-10+ | TRDA | Sethuraman Natarajan | CSO | S - Sale | $18.03 | -17.9K | 153.4K | -10% | -$322.4K |
| D | 2023-06-30 | 2023-06-29 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +8,790 | 36.7K | +31% | +$18.5K |
| DM | 2023-06-23 | 2023-06-21 | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $15.01 | -17.5K | 28.0K | -38% | -$262.6K |
| D | 2023-06-23 | 2023-06-21 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +17.5K | 45.5K | +63% | +$36.8K |
| M | 2023-06-22 | 2023-06-20+ | TRDA | Dowden Nathan J | COO | S - Sale | $15.42 | -16.0K | 49.6K | -24% | -$246.4K |
| 2023-05-01 | 2023-04-27 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $13.71 | -2,000 | 202.1K | -1.0% | -$27.4K | |
| DA | 2023-04-19 | 2023-03-01 | TRDA | KREHER NERISSA | Chief Medical Off | A - Grant | $0.00 | +14.2K | 27.1K | +110% | $0 |
| DA | 2023-04-19 | 2023-03-01 | TRDA | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +14.2K | 28.0K | +103% | $0 |
| DA | 2023-04-19 | 2023-03-01 | TRDA | Sethuraman Natarajan | CSO | A - Grant | $0.00 | +14.2K | 175.3K | +9% | $0 |
| 2023-04-19 | 2023-04-17 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $18.01 | -2,092 | 204.1K | -1% | -$37.7K | |
| DA | 2023-04-19 | 2023-03-01 | TRDA | Dowden Nathan J | COO | A - Grant | $0.00 | +14.2K | 58.5K | +32% | $0 |
| DA | 2023-04-19 | 2023-03-01 | TRDA | Doshi Dipal | Pres, CEO, Dir | A - Grant | $0.00 | +49.6K | 206.2K | +32% | $0 |
| 2023-04-19 | 2023-04-17 | TRDA | Sethuraman Natarajan | CSO | S - Sale | $18.00 | -3,961 | 171.3K | -2% | -$71.3K | |
| M | 2023-03-29 | 2023-03-27 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $14.72 | -2,000 | 256.0K | -0.8% | -$29.4K |
| D | 2023-03-03 | 2023-03-01 | TRDA | Dowden Nathan J | COO | A - Grant | $0.00 | +28.4K | 73.7K | +63% | $0 |
| D | 2023-03-03 | 2023-03-02 | TRDA | Dowden Nathan J | COO | F - Tax | $11.60 | -1,028 | 72.7K | -1% | -$11.9K |
| DM | 2023-03-03 | 2023-03-02 | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale | $10.52 | -1,747 | 42.3K | -4% | -$18.4K |
| D | 2023-03-03 | 2023-03-02 | TRDA | WENTWORTH KORY JAMES | CFO | F - Tax | $11.60 | -1,005 | 43.9K | -2% | -$11.7K |
| D | 2023-03-03 | 2023-03-01 | TRDA | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +28.4K | 44.9K | +172% | $0 |
| D | 2023-03-03 | 2023-03-02 | TRDA | Doshi Dipal | Pres, CEO, Dir | F - Tax | $11.60 | -3,324 | 257.8K | -1% | -$38.6K |
| D | 2023-03-03 | 2023-03-01 | TRDA | Doshi Dipal | Pres, CEO, Dir | A - Grant | $0.00 | +99.3K | 261.1K | +61% | $0 |
| D | 2023-03-03 | 2023-03-01 | TRDA | Sethuraman Natarajan | CSO | A - Grant | $0.00 | +28.4K | 190.5K | +18% | $0 |
| D | 2023-03-03 | 2023-03-02 | TRDA | Sethuraman Natarajan | CSO | F - Tax | $11.60 | -1,058 | 189.5K | -0.6% | -$12.3K |
| DM | 2023-03-03 | 2023-03-02 | TRDA | KREHER NERISSA | Chief Medical Off | S - Sale | $10.56 | -1,641 | 41.5K | -4% | -$17.3K |
| D | 2023-03-03 | 2023-03-02 | TRDA | KREHER NERISSA | Chief Medical Off | F - Tax | $11.60 | -945 | 43.0K | -2% | -$11.0K |
| D | 2023-03-03 | 2023-03-01 | TRDA | KREHER NERISSA | Chief Medical Off | A - Grant | $0.00 | +28.4K | 43.9K | +183% | $0 |
| 2023-03-02 | 2023-02-28 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $12.00 | -2,000 | 161.8K | -1% | -$24.0K | |
| 2023-01-30 | 2023-01-27 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $12.00 | -2,000 | 163.8K | -1% | -$24.0K | |
| 2023-01-10 | 2023-01-09 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $15.02 | -2,410 | 165.8K | -1% | -$36.2K | |
| 2023-01-03 | 2022-12-30 | TRDA | KREHER NERISSA | Chief Medical Off | S - Sale | $13.45 | -5,200 | 15.5K | -25% | -$69.9K | |
| M | 2022-12-29 | 2022-12-27+ | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $15.02 | -14.6K | 182.2K | -7% | -$219.1K |
| D | 2022-12-12 | 2022-12-08 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +4,550 | 21.1K | +28% | +$9,555 |
| D | 2022-12-12 | 2022-12-08 | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $18.95 | -4,550 | 16.5K | -22% | -$86.2K |
| DM | 2022-12-06 | 2022-12-02+ | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $18.19 | -3,110 | 16.5K | -16% | -$56.6K |
| DM | 2022-12-06 | 2022-12-02+ | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +3,110 | 19.4K | +19% | +$6,531 |
| 2022-11-30 | 2022-11-28 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $13.91 | -2,000 | 182.8K | -1% | -$27.8K | |
| D | 2022-11-18 | 2022-11-16 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +200 | 16.7K | +1% | +$420 |
| D | 2022-11-18 | 2022-11-16 | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $18.10 | -200 | 16.5K | -1% | -$3,620 |
| 2022-11-02 | 2022-10-31 | TRDA | Dowden Nathan J | COO | S - Sale | $24.05 | -2,100 | 45.3K | -4% | -$50.5K | |
| M | 2022-10-27 | 2022-10-25+ | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $20.80 | -14.1K | 186.8K | -7% | -$292.5K |
| M | 2022-10-27 | 2022-10-25 | TRDA | Dowden Nathan J | COO | S - Sale | $20.77 | -9,348 | 53.7K | -15% | -$194.2K |
| DM | 2022-10-27 | 2022-10-25+ | TRDA | KREHER NERISSA | Chief Medical Off | S - Sale+OE | $21.27 | -13.0K | 23.8K | -35% | -$276.5K |
| DM | 2022-10-27 | 2022-10-25+ | TRDA | KREHER NERISSA | Chief Medical Off | M - OptEx | $2.10 | +13.0K | 25.7K | +103% | +$27.3K |
| M | 2022-10-24 | 2022-10-20+ | TRDA | Dowden Nathan J | COO | S - Sale | $18.66 | -6,080 | 56.7K | -10% | -$113.4K |
| M | 2022-10-24 | 2022-10-20+ | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $18.64 | -5,939 | 201.2K | -3% | -$110.7K |
| DM | 2022-09-28 | 2022-09-26+ | TRDA | KREHER NERISSA | Chief Medical Off | M - OptEx | $2.10 | +8,593 | 23.8K | +56% | +$18.0K |
| DM | 2022-09-28 | 2022-09-26+ | TRDA | KREHER NERISSA | Chief Medical Off | S - Sale+OE | $15.29 | -8,593 | 20.7K | -29% | -$131.4K |
| M | 2022-09-28 | 2022-09-26 | TRDA | Dowden Nathan J | COO | S - Sale | $15.45 | -1,544 | 63.0K | -2% | -$23.9K |
| M | 2022-09-28 | 2022-09-26+ | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $15.25 | -10.6K | 207.9K | -5% | -$161.4K |
| M | 2022-09-23 | 2022-09-21+ | TRDA | Dowden Nathan J | COO | S - Sale | $15.12 | -4,293 | 64.4K | -6% | -$64.9K |
| M | 2022-09-23 | 2022-09-21+ | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $15.11 | -4,425 | 216.4K | -2% | -$66.9K |
| DM | 2022-09-23 | 2022-09-21+ | TRDA | KREHER NERISSA | Chief Medical Off | M - OptEx | $2.10 | +4,280 | 21.7K | +25% | +$8,988 |
| DM | 2022-09-23 | 2022-09-21+ | TRDA | KREHER NERISSA | Chief Medical Off | S - Sale+OE | $15.08 | -4,280 | 20.7K | -17% | -$64.6K |
| 2022-09-19 | 2022-09-15 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $15.04 | -200 | 219.8K | -0.1% | -$3,008 | |
| D | 2022-09-19 | 2022-09-15 | TRDA | KREHER NERISSA | Chief Medical Off | M - OptEx | $2.10 | +106 | 20.8K | +0.5% | +$222.60 |
| D | 2022-09-19 | 2022-09-15 | TRDA | KREHER NERISSA | Chief Medical Off | S - Sale+OE | $15.01 | -106 | 20.7K | -0.5% | -$1,591 |
| 2022-09-19 | 2022-09-15 | TRDA | Dowden Nathan J | COO | S - Sale | $15.01 | -100 | 68.6K | -0.1% | -$1,501 | |
| M | 2022-09-12 | 2022-09-08+ | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $15.13 | -1,788 | 220.0K | -0.8% | -$27.0K |
| M | 2022-09-12 | 2022-09-08+ | TRDA | Dowden Nathan J | COO | S - Sale | $15.11 | -1,777 | 68.7K | -3% | -$26.8K |
| DM | 2022-09-12 | 2022-09-08+ | TRDA | KREHER NERISSA | Chief Medical Off | S - Sale+OE | $15.11 | -2,021 | 20.7K | -9% | -$30.5K |
| DM | 2022-09-12 | 2022-09-08+ | TRDA | KREHER NERISSA | Chief Medical Off | M - OptEx | $2.10 | +2,021 | 21.9K | +10% | +$4,244 |
| 2022-09-06 | 2022-09-01 | TRDA | KREHER NERISSA | Chief Medical Off | A - Grant | $0.00 | +5,172 | 20.7K | +33% | $0 | |
| 2022-09-06 | 2022-09-01 | TRDA | Dowden Nathan J | COO | A - Grant | $0.00 | +5,632 | 70.5K | +9% | $0 | |
| 2022-09-06 | 2022-09-01 | TRDA | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +5,503 | 16.5K | +50% | $0 | |
| 2022-09-06 | 2022-09-01 | TRDA | Doshi Dipal | Pres, CEO, Dir | A - Grant | $0.00 | +15.1K | 221.8K | +7% | $0 | |
| 2022-09-06 | 2022-09-01 | TRDA | Sethuraman Natarajan | CSO | A - Grant | $0.00 | +5,794 | 162.1K | +4% | $0 | |
| M | 2022-08-31 | 2022-08-29+ | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $12.72 | -2,000 | 206.9K | -1.0% | -$25.4K |
| D | 2022-08-26 | 2022-08-24 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +1,117 | 15.7K | +8% | +$2,346 |
| DM | 2022-08-26 | 2022-08-24+ | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $13.79 | -4,669 | 12.8K | -27% | -$64.4K |
| DM | 2022-08-23 | 2022-08-19+ | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +5,972 | 24.7K | +32% | +$12.5K |
| DM | 2022-08-23 | 2022-08-19+ | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $13.08 | -11.7K | 16.1K | -42% | -$152.5K |
Purchase Sale Sale after option exercise All abbreviations